Program
Interferon beta-1a
Also written as “Rebif®”, “RNF” and “Rebif”.
Its studies are mostly in Multiple Sclerosis · Multiple Sclerosis, Relapsing-Remitting · COVID-19 · Colitis, Ulcerative · Pneumonia, Viral, led by 7 companies.
Drug pageInterferon beta-1a: every studyMany companies study it; this page follows only the 53 they lead. All 82 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Biogen | 230 open or running | phase 4since Sep 13, 2005 | Dec 15, 2004 | none ahead |
| Merck KGaA, Darmstadt, Germanyits history only | 210 open or running | phase 4since Feb 23, 2004 | Feb 23, 2004 | none ahead |
| Faron Pharmaceuticalsits history only | 30 open or running | phase 3since Nov 24, 2015 | Nov 24, 2015 | none ahead |
| Biocadits history only | 20 open or running | phase 3since May 29, 2015 | Jan 10, 2013 | none ahead |
| Cinnagenits history only | 20 open or running | phase 3since Jan 17, 2022 | Jul 14, 2018 | none ahead |
| Azidus Brasilits history only | 10 open or running | phase 1since Nov 13, 2009 | Nov 13, 2009 | none ahead |
| Trio Medicinesits history only | 10 open or running | phase 1since May 20, 2013 | May 20, 2013 | none ahead |
Also a collaborator on its studies: Toray Industries, Pfizer, Gesellschaft für Therapieforschung mbH, Merck Serono S.P.A., Italy, Merck Serono S.A.S, France, EMD Serono Canada, Elan Pharmaceuticals, Merck Pte. Ltd., Singapore and Merck Serono International.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Biogen only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 8 studies since Dec 15, 2004.
- Oct 7, 2008Phase 4 study in Multiple Sclerosis, Relapsing-RemittingNCT00771043
- Oct 29, 2008Phase 3 study in Multiple SclerosisNCT00784836 · 3 enrolled · United States
- Jan 20, 2009Phase 3 study in Multiple SclerosisNCT00828204 · 95 enrolled · United States
- Jun 2, 20092 phase 4 studies in Multiple SclerosisNCT00913666, NCT00915460
- Jun 2, 2009Phase 1 study in Multiple SclerosisNCT00913250 · 96 enrolled
- Jun 2, 2009Phase 2 study in Multiple SclerosisNCT00912860 · 155 enrolled
- Jun 5, 2009Phase 3 study in Multiple SclerosisNCT00915577 · 74 enrolled
- Feb 17, 2010Phase 2 study in Multiple Sclerosis, Relapsing-RemittingNCT01071083 · 175 enrolled · United States, Germany, Spain
- May 6, 2010Phase 1 study in Healthy VolunteersNCT01119677 · 120 enrolled · United States
- Aug 5, 2010Phase 3 study in Multiple SclerosisNCT01181115 · 60 enrolled · China
- Jun 30, 2011Phase 1 study in HealthyNCT01416207 · 24 enrolled · China
- Dec 22, 2011Phase 1 study in Multiple SclerosisNCT01500408 · 110 enrolled · United States
- Oct 17, 2014Phase 1 study in Multiple SclerosisNCT02269930 · 30 enrolled · United States
- Jan 26, 2017Phase 4 study in Multiple Sclerosis, Relapsing-RemittingNCT03177083 · 80 enrolled · Portugal
TargetBeta
“A recombinant form of the endogenous cytokine human interferon (IFN) beta-1a, with antiproliferative, antiviral and immunomodulating activities”NCIt, by rule
“Interferon alpha/beta receptor agonist”ChEMBL 37, by rule
Studies
All 23 Biogen leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03177083Multiple Sclerosis, Relapsing-Remitting · Portugal | 4 | Completed | Oct 26, 2020 | 80 |
| NCT02269930Multiple Sclerosis · United States | 1 | Completed | Dec 2014 | 30 |
| NCT01500408Multiple Sclerosis · United States | 1 | Completed | Apr 2012 | 110 |
| NCT01416207Healthy · China | 1 | Completed | Oct 2011 | 24 |
| NCT01181115Multiple Sclerosis · China | 3 | Completed | Oct 2011 | 60 |
| NCT01119677Healthy Volunteers · United States | 1 | Completed | Oct 23, 2010 | 120 |
| NCT01071083Multiple Sclerosis, Relapsing-Remitting · United States, Germany, Spain | 2 | Completed | Nov 2011 | 175 |
| NCT00915577Multiple Sclerosis | 3 | Completed | Apr 2006 | 74 |
| NCT00915460Multiple Sclerosis | 4 | Completed | Jun 2003 | 408 |
| NCT00913666Multiple Sclerosis | 4 | Completed | 121 | |
| NCT00913250Multiple Sclerosis | 1 | Completed | 96 | |
| NCT00912860Multiple Sclerosis | 2 | Completed | Dec 2004 | 155 |
| NCT00828204Multiple Sclerosis · United States | 3 | Completed | Jul 2010 | 95 |
| NCT00784836Multiple Sclerosis · United States | 3 | Terminated | Feb 2009 | 3 |
| NCT00771043Multiple Sclerosis, Relapsing-Remitting | 4 | Withdrawn | Aug 1, 2009 | 0 |
| NCT00616434Active Ulcerative Colitis · United States, Canada, Czech Republic and more | 2 | Completed | Mar 2010 | 123 |
| NCT00574041Multiple Sclerosis, Relapsing-Remitting · Australia | 4 | Terminated | Feb 2008 | 19 |
| NCT00534261Multiple Sclerosis, Relapsing-Remitting · Belgium, Luxembourg, United Kingdom | 4 | Completed | 284 | |
| NCT00493116Multiple Sclerosis, Relapsing-Remitting · Australia, New Zealand | 4 | Completed | Dec 2009 | 20 |
| NCT00493077Multiple Sclerosis · Sweden | 4 | Completed | May 2006 | 3 |
| NCT00492466Multiple Sclerosis, Relapsing-Remitting · Finland | 4 | Completed | Aug 2006 | 14 |
| NCT00168766Multiple Sclerosis, Relapsing-Remitting · Belgium, Denmark, Finland and more | 4 | Completed | Nov 2008 | 345 |
| NCT00099489Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Australia, Canada and more | 2 | Completed | Feb 2006 | 67 |
How it is read
Names in the registry
- “Interferon beta-1a”, 11 entries
- “Rebif®”, 7 entries
- “RNF”, 5 entries
- “Rebif”, 4 entries
- “SNG001”, 3 entries
Conditions, from the studies’ own filings
- Multiple Sclerosis, 21 studies
- Multiple Sclerosis, Relapsing-Remitting, 18 studies
- COVID-19, 3 studies
- Colitis, Ulcerative, 2 studies
- Pneumonia, Viral, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.